切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2024, Vol. 18 ›› Issue (01) : 76 -80. doi: 10.3877/cma.j.issn.1674-0793.2024.01.015

综述

胆管癌的光动力治疗
高彬, 阿曼塔依·努尔塔依, 宁江红, 邵英梅()   
  1. 830054 乌鲁木齐,新疆医科大学第一附属医院消化血管外科中心肝胆包虫病外科
  • 收稿日期:2023-08-03 出版日期:2024-02-01
  • 通信作者: 邵英梅
  • 基金资助:
    省部共建中亚高发病成因与防治国家重点实验室开放课题(SKL-HIDCA-2020-BC); 省部共建中亚高发病成因与防治国家重点实验室开放课题(SKL-HIDCA-2021-12); 新疆维吾尔自治区高校科研计划项目(XJEDU2021I016)

Photodynamic therapy of cholangiocarcinoma

Bin Gao, Nuertayi Amantayi·, Jianghong Ning, Yingmei Shao()   

  1. Department of Hepatobiliary Hydatid Diseases, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
  • Received:2023-08-03 Published:2024-02-01
  • Corresponding author: Yingmei Shao
引用本文:

高彬, 阿曼塔依·努尔塔依, 宁江红, 邵英梅. 胆管癌的光动力治疗[J]. 中华普通外科学文献(电子版), 2024, 18(01): 76-80.

Bin Gao, Nuertayi Amantayi·, Jianghong Ning, Yingmei Shao. Photodynamic therapy of cholangiocarcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(01): 76-80.

胆管癌发病隐匿且恶性程度较高,通常在发现时已达疾病晚期,已丧失根治性手术切除机会。对于晚期胆管癌的姑息性治疗,传统手段常包括胆道支架置入、射频消融术、放化疗等,但胆管癌对放化疗并不敏感。近年来,光动力疗法(PDT)成为了晚期胆管癌患者的另一项选择,作为一种创伤小、不良反应少的治疗方式,逐步应用于晚期胆管癌的姑息性治疗且已取得良好的疗效,引起了学术界的广泛关注。本文从PDT的原理、在胆管癌中的应用及优缺点等方面进行综述。

Changiocarcinoma, insidious and highly malignant, is usually at the advanced stage when it is found out, and patients have lost the chance of radical surgical resection. For the palliative treatment of advanced cholangiocarcinoma, traditional methods include biliary stent placement, radiofrequency ablation, chemoradiotherapy and so on, but cholangiocarcinoma is not sensitive to chemoradiotherapy. In recent years, photodynamic therapy (PDT) has become another option for patients with advanced cholangiocarcinoma due to less trauma and adverse effects. It has been gradually applied to the palliative treatment of advanced cholangiocarcinoma and has achieved good results, thus attracts wide attention in the academic community. This paper summarizes the principles, advantages and disadvantages of the application of PDT for changiocarcinoma.

[1]
Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide[J]. Hepatology, 2018, 67(2): 600-611.
[2]
Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis[J]. Am J Gastroenterol, 2000, 95(1): 204-207.
[3]
Höblinger A, Gerhardt T, Gonzalez-Carmona MA, et al. Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma[J]. Eur J Med Res, 2011, 16(9): 391-395.
[4]
Lu Y, Liu L, Wu JC, et al. Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): 718-724.
[5]
Donohoe C, Senge MO, Arnaut LG, et al. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(2): 188308.
[6]
袁耒, 邹志强, 李传海, 等. 早期食管癌的光动力治疗[J/CD]. 中华消化病与影像杂志(电子版), 2022, 12(5): 306-309.
[7]
Dichiara M, Prezzavento O, Marrazzo A, et al. Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents[J]. Eur J Med Chem, 2017, 142: 459-485.
[8]
Obaid G, Broekgaarden M, Bulin AL, et al. Photonanomedicine: A convergence of photodynamic therapy and nanotechnology[J]. Nanoscale, 2016, 8(25): 12471-12503.
[9]
Li Z, Jiang X, Xiao H, et al. Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma[J]. Surg Endosc, 2021, 35(10): 5655-5664.
[10]
Brunaldi VO, Brunaldi JE, Vollet-Filho JD, et al. Photodynamic therapy of extrahepatic cholangiocarcinoma using digital cholangioscopy[J]. Arq Bras Cir Dig, 2020, 33(1): e1490.
[11]
Talreja JP, DeGaetani M, Sauer BG, et al. Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment[J]. Photochem Photobiol Sci, 2011, 10(7): 1233-1238.
[12]
Choi HJ, Moon JH, Ko BM, et al. Clinical feasibility of direct peroral cholangioscopy-guided photodynamic therapy for inoperable cholangiocarcinoma performed by using an ultra-slim upper endoscope (with videos)[J]. Gastrointest Endosc, 2011, 73(4): 808-813.
[13]
Zhou J, Xiong L, Liu W, et al. SpyGlass-guided photodynamic therapy for unresectable cholangiocarcinoma: A case report and review of the literature[J]. Front Oncol, 2022, 12: 890735.
[14]
Choi JH, Oh D, Lee JH, et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter[J]. Endoscopy, 2015, 47(11): 1035-1038.
[15]
宋铭杰, 韩青雷, 李佳隆, 等. 内镜下晚期肝外胆管恶性肿瘤消融治疗研究现况[J/CD]. 中华普外科手术学杂志(电子版), 2023, 17(3): 340-342.
[16]
Pereira SP, Jitlal M, Duggan M, et al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer[J]. ESMO Open, 2018, 3(5): e000379.
[17]
许博, 席大勇, 蒲唯高, 等. 双金属支架联合光动力治疗及靶向、免疫治疗在远端胆管癌中的应用[J]. 肝胆胰外科杂志, 2021, 33(7): 427-433.
[18]
Moole H, Tathireddy H, Dharmapuri S, et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis[J]. World J Gastroenterol, 2017, 23(7): 1278-1288.
[19]
Mohan BP, Chandan S, Khan SR, et al. Photodynamic therapy (PDT), radiofrequency Ablation (RFA) with biliary stents in palliative treatment of unresectable extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2022, 56(2): e153-e160.
[20]
Song S, Gong S, Lei T, et al. Comparative efficacy and safety of local palliative therapeutics for unresectable malignant biliary obstruction: A Bayesian network meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2022, 16(6): 555-567.
[21]
Schmidt A, Bloechinger M, Weber A, et al. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma[J]. United European Gastroenterol J, 2016, 4(4): 570-579.
[22]
Beltrán Hernández I, Yu Y, Ossendorp F, et al. Preclinical and clinical evidence of immune responses triggered in oncologic photodynamic therapy: clinical recommendations[J]. J Clin Med, 2020, 9(2): 333.
[23]
Yu Y, Wang N, Wang Y, et al. Photodynamic therapy combined with systemic chemotherapy for unresectable extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2023, 41: 103318.
[24]
Wentrup R, Winkelmann N, Mitroshkin A, et al. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma[J]. Gut Liver, 2016, 10(3): 470-475.
[25]
Gonzalez-Carmona MA, Bolch M, Jansen C, et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma[J]. Aliment Pharmacol Ther, 2019, 49(4): 437-447.
[26]
卢学敏, 刘黎, 许泓, 等. 光化学内化作用及其在基因输送中的应用[J]. 上海交通大学学报(医学版), 2018, 38(3): 353-356.
[27]
Trojan J, Hoffmeister A, Neu B, et al. Photochemical internalization of gemcitabine is safe and effective in locally advanced inoperable cholangiocarcinoma[J]. Oncologist, 2022, 27(6): e430-e433.
[28]
Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: A phase Ⅱ pilot study[J]. Cancer, 2003, 97(11): 2783-2790.
[29]
Wagner A, Wiedmann M, Tannapfel A, et al. Neoadjuvant down-sizing of hilar cholangiocarcinoma with photodynamic therapy--long-term outcome of a phase Ⅱ pilot study[J]. Int J Mol Sci, 2015, 16(11): 26619-26628.
[30]
Grendar J, Grendarova P, Sinha R, et al. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: A systematic review[J]. HPB (Oxford), 2014, 16(4): 297-303.
[31]
Sapisochin G, de Lope CR, Gastaca M, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A Spanish matched cohort multicenter study[J]. Ann Surg, 2014, 259(5): 944-952.
[32]
Vilchez V, Shah MB, Daily MF, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: An analysis of the UNOS database[J]. HPB (Oxford), 2016, 18(1): 29-34.
[33]
Cosgrove ND, Al-Osaimi AM, Sanoff HK, et al. Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation[J]. Am J Transplant, 2014, 14(2): 466-471.
[1] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[2] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[3] 李佳隆, 韩青雷, 宋铭杰, 古丽米拉·亚森江, 钟锴, 蒋铁民, 郭强, 吐尔干艾力·阿吉, 邵英梅. Bismuth-Corlette Ⅱ型肝门部胆管癌行扩大肝切除与围肝门切除的临床疗效分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 438-443.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[6] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[7] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[8] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[9] 汪洋, 李志鹏, 王可兵. 上尿路尿路上皮癌术后预防性膀胱灌注化疗的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 649-652.
[10] 刘恒, 侯宇川. 膀胱癌新型灌注药物的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 445-451.
[11] 张伟, 赵芸芳, 郝建东, 李海. 安罗替尼联合化疗Ⅳ期NSCLC的CA125、MALAT1、VECF及临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 849-851.
[12] 陈艳, 王安康, 梁风玲, 黄垂志, 陈山. DCE-MRI在肺癌BACE疗效判断中的临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 871-873.
[13] 张宇, 余灵祥, 杨永平, 赵德希, 刁广浩, 杨木易, 赵亮, 刘佳, 李鹏, 张宁, 任辉. 原发性肝癌Ⅲa期降期后肝切除临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 78-82.
[14] 陈明政, 栗玉龙, 唐流康, 谢峰. IDH1突变应用于肝内胆管癌治疗的研究进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 103-108.
[15] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
阅读次数
全文


摘要